Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins perform adaptive immune functions in prokaryotic organisms defending against foreign nucleic acids such as viruses. CRISPR/Cas tools have been adapted for use in genome editing and other DNA and RNA targeting applications.
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR associatedCRISPR-associated (Cas) proteins perform adaptive immune functions in prokaryotic organisms defending against foreign nucleic acids such as viruses. CRISPR/Cas tools have been adapted for use in genome editing and other DNA and RNA targeting applications.
Class 1
The CRISPR-Cas systems belong to two classes, with multi-subunit effector complexes in Class 1 and single-protein effector modules in Class 2.
The effector complexes of type I and type III consist of a backbone of paralogous Repeat-Associated Mysterious Proteins (RAMPs) such as Cas7 and Cas5 with the RNA Recognition Motif (RRM) fold and additional large and small subunits.
Type I
Type III
Type IV
Class 2
The effector modules in classClass 2 are a single multi-domain protein and have a simpler and more uniform organization compared with classClass 1.
Type II
There are many variants of Cas9 from different prokaryotic species. Smaller sized versions of Cas9 are favorable for packaging and delivery into cells but there is a tradeoff in that smaller Cas9 proteins need a more complex PAM sequence which limits where they can target the genome. In parallel to research into gaining better understanding of and identification of new Cas proteins, there are efforts to re-engineer Cas9 proteins to reduce their size, increase fidelity and expand the target scope. CRISPR-Cas9 was the first CRISPR system used to edit human cells and is commonly used in genetic engineering and molecular biology applications.
Type IV
Type V
Type VI
Type VI effectors all contain HEPN domains, which give them RNase activity, allowing them to target and degrade RNA.
CRISPR has revolutionalizedrevolutionized the genome editing field because it is simpler and more flexible to use than other genome editing tools such as meganucleases, ZFNs, and TALENs.
Genome editing with CRISPR-Cas9 has been demonstrated in model species such as Arabidopsis, rice, and tobacco as well as a few crop species. CRISPR-Cas12a genome editing has also been demonstrated to work in plants. The United States Department of AgricultureUnited States Department of Agriculture (USDA) stated that CRISPR-Cas9 edited crops will not be regulated as GMO.
CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) are gene regulation tools that use a nuclease deactivatednuclease-deactivated version of Cas9 called dCas9. Gene expression is inhibited by dCas9 coexpressed with a guide RNA by interfering with RNA polymerase binding, transcriptional elongation, or transcription factor binding. When dCas9 is fused with the omega subunit of RNA polymerase or transcriptional activators, gene expression is enhanced.
The organization of genes within the genome and their location within chromatin architecture, such as chromatin loop structures, is important for gene regulation programs in development and disease.
CAS-EXPAR (CRISPR/Cas9-triggered isothermal exponential amplification reaction) was developed to detect Listeria monocytogenes, a foodborne pathogen found in milk, milk products, eggs, poultry and meat which can cause invasive listeriosis and severe illness in young, elderly and immunocompromised individuals.
Genetic screening of mutant libraries is a way to search for genes involved in a desired pathway where mutant genes produce a certain phenotype. CRISPR libraries contain thousands of plasmids with multiple guide RNAs (gRNAs) for each target gene. Cells are treated with the library gRNA and Cas9, creating a population of mutant cells whichthat can be screened for a phenotype of interest. CRISPR libraries can knockout, activate, or repress target genes. The following companies and non-profitsnonprofits sell or distribute CRISPR libraries.
Anti-CRISPR proteins are a defense mechanism whichthat evolved in phages to escape destruction from CRISPR in their host prokaryotes. Anti-CRISPR proteins have applications as an “off switch” for CRISPR basedCRISPR-based genome editing or for reducing off-target cutting by CRISPR systems.
CRISPR/Cas systems are used to target sites of interest within the cell and attach a label, such as fluorescence, to allow them to be visualized.
Recombineering is a method of genetic engineering in bacterial genomes that involves homologous recombination. In contrast to CRISPR used for gene editing in eukaryotic cells, CRISPR assists the selection of successful recombineering events whichthat change the target sequence and negatively selects cells in which the desired homologous recombination has not occurred. Negative selection occcursoccurs by CRISPR-Cas9 induced double strandeddouble-stranded breaks, which are lethal in bacteria where non homologousnon-homologous end joining (NHEJ) is not very effective.
Based on the ability of CRISPR systems to sequentially acquire DNA sequences from viral infections, adding them to spacer sequences in a growing array in the CRISPR locus, molecular recorder tools are being developed whichthat can record information provided by researchers or from the cell interactions with the environment.
CRISPR/Cas systems are used to target sites of interest within the cell and attach a label such as fluorescence to allow them to be visualized.
Genome editing with CRISPR-Cas9 has been demonstrated in model species such as Arabidopsis, rice and tobacco as well as a few crop species. CRISPR-Cas12a genome editing has also been demonstrated to work in plants. The United States Department of Agriculture (USDA) stated that CRISPR-Cas9 edited crops will not be regulated as GMO.
The following crops have been improved using CRISPR-Cas9 technology:
Genome editing with CRISPR-Cas9 has been demonstrated in model species such as Arabidopsis, rice and tobacco as well as a few crop species. CRISPR-Cas12a genome editing has also been demonstrated to work in plants. The United States Department of Agriculture (USDA) stated that CRISPR-Cas9 edited crops will not be regulated as GMO.
The following crops have been improved using CRISPR-Cas9 technology:
Nucleic acid testing is used to screen and diagnose diseases and conditions. For nucleic acid testing, CRISPR systems are adapted to target nucleic acid sequences that are markers for disease and act as biosensors detecting pathogenic bacteria and viruses.
RAA-CRISPR/Cas12a (recombinase aided amplification assisted CRISPR/Cas12a) was developed to detect E. coli 05157:H7 and was shown to be accurate and sensitive in beef samples spiked with the bacteria.
CAS-EXPAR (CRISPR/Cas9-triggered isothermal exponential amplification reaction) was developed to detect Listeria monocytogenes, a foodborne pathogen found in milk, milk products, eggs, poultry and meat which can cause invasive listeriosis and severe illness in young, elderly and immunocompromised individuals.
CRISPR/Cas13a (APC-Cas) is a system that combines CRISPR with an allosteric probe (AP) that targets whole bacteria (Salmonella enteritidis).
Nucleic acid testing is used to screen and diagnose diseases and conditions. For nucleic acid testing, CRISPR systems are adapted to target nucleic acid sequences that are markers for disease.
RecombineeringRecombineering is a method of genetic engineering in bacterial genomes that involves homologous recombination. In contrast to CRISPR used for gene editing in eukaryotic cells, CRISPR assists the selection of successful recombineering events which change the target sequence and negatively selects cells in which the desired homologous recombination has not occurred. Negative selection occcurs by CRISPR-Cas9 induced double stranded breaks which are lethal in bacteria where non homologous end joining (NHEJ) is not very effective.
CRISPR-Cas systems are being developedcombined with phage therapy to target and degrade DNA of pathogenic bacteria as a selective antimicrobial treatment
CRISPR-Cas3CRISPR-Cas issystems are being developed by Locus Biosciences to target and degrade the DNA of pathogenic bacteria in orderas toa killselective it.antimicrobial treatment